McMillan Robert R, Berger Alexandra, Sima Camelia S, Lou Feiran, Dycoco Joseph, Rusch Valerie, Rizk Nabil P, Jones David R, Huang James
Thoracic Service, Department of Surgery, Memorial Sloan Kettering Cancer Center, New York, New York.
Thoracic Service, Department of Surgery, Memorial Sloan Kettering Cancer Center, New York, New York.
Ann Thorac Surg. 2014 Nov;98(5):1769-74; discussion 1774-5. doi: 10.1016/j.athoracsur.2014.06.024. Epub 2014 Sep 8.
Operative mortality rates are of great interest to surgeons, patients, policy makers, and payers as a metric for quality assessment. Thirty-day mortality and discharge mortality have been presumed to capture procedure-related deaths. However, many patients die after the 30-day mark or are transferred to other facilities or to home and die there, leading to the underreporting of surgically related deaths. We hypothesized that a longer period of observation would address these concerns and provide a more accurate measure of operative mortality.
We retrospectively reviewed institutional databases of patients undergoing resection for lung cancer, esophageal cancer, and mesothelioma. Mortality rates at 30 and 90 days were calculated with 95% confidence intervals (CIs).
From 1999 to 2012, 7,646 surgical resections were performed: 6,119 for lung cancer, 1,258 for esophageal cancer, and 269 for mesothelioma. Among the different cancers and across operations, the additional mortality from day 31 to 90 (1.4%; 95% CI, 1.2% to 1.8%; n=111) was similar to that by day 30 (1.2%; 95% CI, 1.0% to 1.5%; n=95), resulting in overall 90-day mortality (2.7%; 95% CI, 2.3% to 3.1%; n=206) that was more than double the 30-day mortality.
Among patients who have undergone operations for thoracic malignancies, mortality attributable to the operation occurs beyond the first 30 postsurgical days as well as after hospital discharge. Because cancer operations constitute a large portion of general thoracic surgery, we recommend national databases consider the inclusion of 90-day mortality in their data collection.
手术死亡率作为质量评估指标,受到外科医生、患者、政策制定者和支付方的高度关注。30天死亡率和出院死亡率被认为可反映与手术相关的死亡情况。然而,许多患者在30天之后死亡,或被转至其他机构或家中并在那里死亡,导致手术相关死亡报告不足。我们推测,延长观察期可解决这些问题,并能更准确地衡量手术死亡率。
我们回顾性分析了接受肺癌、食管癌和间皮瘤切除术患者的机构数据库。计算了30天和90天的死亡率及95%置信区间(CI)。
1999年至2012年,共进行了7646例手术切除:肺癌6119例,食管癌1258例,间皮瘤269例。在不同癌症及各类手术中,第31天至90天的额外死亡率(1.4%;95%CI,1.2%至1.8%;n = 111)与第30天的死亡率(1.2%;95%CI,1.0%至1.5%;n = 95)相似,导致90天总死亡率(2.7%;95%CI,2.3%至3.1%;n = 206)超过30天死亡率的两倍。
在接受胸部恶性肿瘤手术的患者中,手术相关死亡不仅发生在术后的前30天内,也发生在出院后。由于癌症手术占普通胸外科手术的很大一部分,我们建议国家数据库在数据收集中考虑纳入90天死亡率。